About NCCU Academics Admissions Athletics Campus Life Giving Research

Welcome To North Carolina Central University

Development of an active PCSK9 Assay to be Used in Human Serum Sample

PCSK9 increases the degradation of the LDL receptor in response to statin therapy, and due to that, this protease has been made responsible for the decline in the drug’s ability to continue reducing serum LDL levels. Therefore, the current goal is to come up with an inhibitor for PCSK9 to supplement statin therapy. In this project, we intend to adapt an assay to detect how much PCSK9 is available to bind the LDL receptor (active PCSK9) and to characterize the endogenous inhibitor of PCSK9.

Registry Form

To register for the [research project name], click here.


  • No related projects found.


  • Chronic Disease


About The Team

  • No members specified.


  • No sponsors found.


  • No collaborators found.